Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM
- 31 July 2010
- journal article
- research article
- Published by Elsevier BV in Leukemia Research
- Vol. 34 (7), 864-870
- https://doi.org/10.1016/j.leukres.2009.12.004
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Myelodysplastic Syndrome (MDS)-Specific Comorbidity Index for Predicting the Impact of Extra-Hematological Comorbidities on Survival of Patients with MDSBlood, 2008
- Hematopoietic cell transplantation‐comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantationCancer, 2008
- Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experienceBlood, 2008
- Age and Comorbidity As Independent Prognostic Factors in the Treatment of Non–Small-Cell Lung Cancer: A Review of National Cancer Institute of Canada Clinical Trials Group TrialsJournal of Clinical Oncology, 2008
- Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q DeletionNew England Journal of Medicine, 2006
- Prognostic Factors and Life Expectancy in Myelodysplastic Syndromes Classified According to WHO Criteria: A Basis for Clinical Decision MakingJournal of Clinical Oncology, 2005
- The World Health Organization Classification of Hematological Malignancies Report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997Laboratory Investigation, 2000
- Long-term blood product transfusion support for patients with myelodysplastic syndromes (MDS): cost analysis and complicationsLeukemia Research, 1999
- MyelodysplasiaNew England Journal of Medicine, 1999
- Proposals for the classification of the myelodysplastic syndromesBritish Journal of Haematology, 1982